CCDM Certification Overview - [Jan 31, 2026] Latest CCDM PDF Dumps
The Best SCDM CCDM Study Guides and Dumps of 2026
NEW QUESTION # 33
A study team member suggests that data for a small, 50-patient, 2-year study can be entered and cleaned in two weeks before lock. Which are important other considerations?
- A. Processing the data in two weeks after the study is over would save money because the data manager would not be involved until the end
- B. Processing the data in two weeks after the study is over would save money because the EDC system would only be needed for a month
- C. It would take more than two weeks to get second iteration queries generated and resolved
- D. Without the ability to capture the data electronically, the data cannot be checked or used to monitor and manage the study
Answer: C
Explanation:
The most critical consideration is that data cleaning is an iterative process, and completing all necessary steps - including query generation, site resolution, and second-pass validation - cannot realistically be accomplished within two weeks after study close.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Validation and Cleaning), data cleaning must occur continuously throughout the study, not only at the end. Post-database lock activities typically include running final validation checks, resolving outstanding queries, performing reconciliation (e.g., SAEs, labs, coding), and conducting final quality review.
Even in small studies, query turnaround and response cycles from sites take time - typically 2-4 weeks per iteration - making a two-week total cleaning period unrealistic.
Therefore, Option D is correct: it would take more than two weeks to handle second-round (follow-up) queries and confirm final resolutions prior to database lock.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 5.4 - Ongoing vs. End-of-Study Data Cleaning ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Quality and Timeliness FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Management and Cleaning
NEW QUESTION # 34
The Medical Dictionary for Regulatory Activities (MedDRA) structure is in which of the following hierarchical orders, from most specific to least specific?
- A. LLT, HLGT, PT, HLT, SOC
- B. LLT, PT, HLT, HLGT, SOC
- C. LLT, PT, HLGT, HLT, SOC
- D. LLT, HLGT, HLT, PT, SOC
Answer: B
Explanation:
The MedDRA (Medical Dictionary for Regulatory Activities) is a standardized medical terminology used for coding and analyzing adverse event (AE) and medical history data in clinical trials. Its hierarchical structure supports aggregation, analysis, and reporting across varying levels of medical specificity.
From most specific to least specific, the hierarchy is as follows:
Lowest Level Term (LLT): The most granular term, often reflecting the verbatim text reported by the investigator.
Preferred Term (PT): The standardized medical concept representing one or more LLTs describing the same condition.
High Level Term (HLT): A grouping of related PTs describing similar medical conditions.
High Level Group Term (HLGT): A broader grouping of related HLTs.
System Organ Class (SOC): The highest level of classification, grouping HLGTs by body system or etiology (e.g., cardiac disorders, infections).
Thus, the correct order - from most specific to least specific - is:
LLT → PT → HLT → HLGT → SOC, which corresponds to option D.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Medical Coding and Dictionaries, Section 5.2 - MedDRA Hierarchical Structure ICH M1 MedDRA Terminology Guide, Version 26.0 - Hierarchy Overview ICH E2B(R3) Guidelines - Clinical Safety Data Management
NEW QUESTION # 35
A Data Manager receives an audit finding of three different instances of simultaneous log-ins to the EDC system by the same site user. This was observed at three different sites. Which of the following is the best long-term response to the audit finding?
- A. Requesting that the sites fire the offending users for a HIPAA violation and increasing the monitoring for the offending sites
- B. Removing all access to the system until the situation is resolved
- C. Acquiring technical controls from the same or a different system vendor that prevent simultaneous log-ins from the same user
- D. Refresher training for the offending users, re-communication of the binding nature of e-signatures to all users, routine monitoring for simultaneous log-ins from the same user
Answer: D
Explanation:
The best long-term corrective and preventive action (CAPA) in this situation is a combination of user re-training, communication, and routine monitoring - as described in Option B.
According to the GCDMP (Chapter: Electronic Data Capture Systems) and FDA 21 CFR Part 11, user credentials and electronic signatures in clinical systems are legally binding and must be used only by the assigned individual. Simultaneous log-ins under the same credentials often indicate credential sharing, a compliance violation that must be addressed through user education, reinforced security policies, and ongoing system oversight.
While technical controls (option A) may be considered, behavioral and procedural reinforcement are the first lines of defense. Options C and D are excessive and not aligned with proportional CAPA practices.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 7.1 - User Access, Authentication, and Training FDA 21 CFR Part 11 - Electronic Records and Electronic Signatures, Sections 11.10(i) and 11.200(a) ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Access Control and Audit Trail Requirements
NEW QUESTION # 36
Which of the following SOPs are required for management of an EDC system?
- A. Maintenance of coding dictionaries
- B. Management of vendors
- C. Measurement of data quality
- D. Change control
Answer: D
Explanation:
The most essential Standard Operating Procedure (SOP) for management of an Electronic Data Capture (EDC) system is Change Control.
Per GCDMP (Chapter: Computerized Systems and Compliance) and FDA 21 CFR Part 11, any changes made to an EDC system-whether to software configuration, study database design, or system functionality-must follow a documented, validated, and auditable change control process. This ensures that:
Modifications are properly authorized, tested, and approved before implementation.
System validation remains intact.
Data integrity, traceability, and regulatory compliance are maintained.
While vendor management (A) and coding maintenance (C) have supporting SOPs, change control (D) is mandatory for any system handling regulated clinical data. Measurement of data quality (B) is important but not specifically tied to system management procedures.
Thus, option D (Change control) is the correct answer.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 5.3 - Change Control and System Maintenance FDA 21 CFR Part 11 - Electronic Records and Electronic Signatures, Section 11.10(a-k) ICH E6(R2) GCP, Section 5.5.3 - Computerized Systems Validation and Change Documentation
NEW QUESTION # 37
A study numbers subjects sequentially within each site and does not reuse site numbers. Which information is required when joining data across tables?
- A. Study number and subject number
- B. Site number
- C. Subject number
- D. Subject number and site number
Answer: D
Explanation:
When subjects are numbered sequentially within each site, it means that the subject identification numbers (Subject IDs) restart from 001 at each site. For example, Site 101 may have Subject 001, and Site 102 may also have a Subject 001. In such cases, the subject number alone is not globally unique across the entire study. Therefore, when integrating or joining data across multiple database tables (for example, linking demographic, adverse event, and laboratory data), both the site number and the subject number are required to create a unique key that accurately identifies each record.
According to the Good Clinical Data Management Practices (GCDMP, Chapter on CRF Design and Data Collection), every data record in a clinical trial database must be uniquely and unambiguously identified. This is typically achieved through a composite key, combining identifiers such as site number, subject number, and sometimes study number. The GCDMP specifies that a robust data structure must prevent duplication or mislinking of records across domains or tables.
Furthermore, FDA and CDISC standards (SDTM model) also emphasize the importance of unique subject identifiers (USUBJID), which are derived from concatenating the study ID, site ID, and subject ID. This ensures traceability, integrity, and accuracy of subject-level data during database joins, data exports, and regulatory submissions.
Thus, in the described scenario, since subject numbering restarts at each site, both the site number and subject number are required to uniquely identify and correctly join subject data across different datasets or tables.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 4.1 - Unique Subject Identification CDISC SDTM Implementation Guide, Section 5.2 - Subject and Site Identification (Variable: USUBJID) FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6 - Data Integrity and Record Identification
NEW QUESTION # 38
An asthma study is taking into account local air quality and receives that data from the national weather bureau. Which information is needed to link research subject data to the air-quality readings?
- A. Location and time identifiers
- B. Location, time, subject and site identifiers
- C. Location identifier
- D. Location, time and subject identifiers
Answer: A
Explanation:
When integrating external environmental data such as air quality readings with clinical study data, it is essential to use location and time identifiers to properly align the environmental data with subject-level data.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Management Planning and Study Start-up), external data sources (like national weather or pollution databases) must be merged using common linkage variables that allow synchronization without breaching subject confidentiality. In this case:
Location identifiers (e.g., city, postal code, or region) align the subject's study site or residential area with the environmental dataset.
Time identifiers (e.g., date and time of data collection) ensure that the environmental readings correspond to the same period as the subject's clinical observations.
Including subject identifiers (option C or D) is unnecessary and would pose privacy and data protection risks. Instead, linkage is typically done at the aggregate (site or regional) level, maintaining compliance with HIPAA and GDPR.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Integration and External Data Handling, Section 4.3 - Linking External Data Sources ICH E6 (R2) GCP, Section 5.5.3 - Data Traceability and External Data Management FDA Guidance for Industry: Use of Electronic Health Record Data in Clinical Investigations, Section 5.2 - Linking and Integration Principles
NEW QUESTION # 39
Which method would best identify clinical chemistry lab data affected by a blood draw taken distal to a saline infusion?
- A. Lab values from a blood draw with a very low sodium and very high other values
- B. Lab values from a blood draw with a very high sodium and very low other values
- C. Abnormally high sodium values in a dataset
- D. Abnormally low urine glucose values in a dataset
Answer: B
Explanation:
If a blood sample is drawn distal (downstream) from a saline infusion site, it may become contaminated with saline, leading to abnormal laboratory results. Saline contains a high concentration of sodium chloride, which artificially elevates sodium while diluting other blood components.
Therefore, such samples would display:
Very high sodium levels, and
Abnormally low levels of other analytes (e.g., proteins, glucose, potassium).
This abnormal pattern (option B) is a classic indicator of saline contamination.
Per the GCDMP (Chapter: Data Validation and Cleaning), cross-variable consistency checks are critical for identifying biologically implausible patterns, such as this one, which indicate pre-analytical errors rather than true physiological changes.
Hence, option B accurately describes the data signature of a contaminated blood draw.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 6.2 - Logical and Consistency Checks for Laboratory Data ICH E6(R2) GCP, Section 5.1.1 - Data Quality and Biological Plausibility Checks FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 - Detecting Laboratory Anomalies
NEW QUESTION # 40
Which is a minimum prerequisite that should be in place before choosing an EDC system?
- A. Draft validation plan
- B. Updated governance documentation
- C. Knowledge of functional requirements
- D. Completed installation qualification
Answer: C
Explanation:
Before selecting an Electronic Data Capture (EDC) system for a clinical trial, it is essential to have a clear understanding of the functional requirements. This serves as the minimum prerequisite to guide system selection, ensuring that the EDC solution aligns with the protocol needs, data workflow, security requirements, and regulatory compliance.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Computerized Systems and Compliance), functional requirements describe what the system must do-such as data entry capabilities, edit checks, query management, user roles, audit trails, and integration with external systems (e.g., labs, ePRO). This understanding allows sponsors and CROs to evaluate vendor systems effectively during the selection and qualification phase.
Other options:
B . Installation qualification and D. Validation plan occur after system selection.
C . Governance documentation supports operations but is not required before choosing the system.
Hence, option A is correct - the first and most essential prerequisite before EDC selection is a solid understanding of the functional requirements.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 4.2 - Requirements Gathering and System Selection FDA 21 CFR Part 11 - System Validation and Intended Use Requirements ICH E6(R2) GCP, Section 5.5.3 - Computerized System Selection and Qualification
NEW QUESTION # 41
Which of the following tasks would be reasonable during a major upgrade of a clinical data management system?
- A. All of the data formats in the archive should be updated to new standards.
- B. The data archive should be migrated to an offsite database server.
- C. The ability to access and read the clinical data archive should be tested.
- D. All of the case report forms should be pulled and compared to the archive.
Answer: C
Explanation:
During a major system upgrade, it is critical to verify that archived data remain accessible, readable, and intact following the implementation.
According to the GCDMP (Chapter: Database Lock and Archiving), regulatory requirements such as 21 CFR Part 11 and ICH E6(R2) mandate that archived data must remain retrievable in a human-readable format for the duration of retention (often years after study completion).
Therefore, as part of validation and verification testing, organizations must confirm that existing archives can still be accessed using the upgraded system or compatible tools.
Option A: Updating archive formats could alter original data integrity (noncompliant).
Option C: Migration offsite is an IT infrastructure task, not directly tied to the upgrade process.
Option D: Comparing CRFs to archives is unnecessary unless data corruption is suspected.
Hence, option B (testing archive accessibility) is the correct and compliant approach.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.4 - System Upgrades and Archive Validation ICH E6(R2) GCP, Section 5.5.3 - System Validation and Data Retention FDA 21 CFR Part 11 - Data Archiving, Retention, and Retrieval Requirements
NEW QUESTION # 42
What action should be taken regarding the clinical database when MedDRA releases a new version of its dictionary?
- A. Continue using the existing version to code.
- B. Evaluate the extent and impact of the changes.
- C. Upgrade the version immediately and recode.
- D. Identify an alternative dictionary.
Answer: B
Explanation:
When a new version of MedDRA (Medical Dictionary for Regulatory Activities) is released, the correct action is to evaluate the extent and impact of the changes before implementation.
According to the GCDMP (Chapter: Medical Coding and Dictionaries), MedDRA updates are published twice yearly (March and September). Each release may introduce new terms, modify hierarchies, or retire old ones. Prior to adopting a new version, the Data Manager and Medical Coder must:
Assess the number and type of term changes,
Determine the potential effect on ongoing coding consistency, and
Decide whether migration to the new version is warranted mid-study or deferred until database lock.
Immediate recoding (option C) without evaluation may cause inconsistencies and require additional validation. Continuing with the existing version (option B) may be acceptable short-term but must be justified. Using an alternative dictionary (option D) is noncompliant, as MedDRA is the regulatory standard for safety reporting.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Medical Coding and Dictionaries, Section 6.3 - Version Control and Impact Assessment MedDRA Term Selection: Points to Consider (MSSO, Latest Version), Section 3 - Versioning and Maintenance ICH E2B(R3) - Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports
NEW QUESTION # 43
What method is used for quality control of the query resolution process?
- A. Calculate the time from discrepancy identified to query sent.
- B. Perform random audits of the resolved query forms.
- C. Calculate the time from query sent to query resolution from the site.
- D. Tabulate the number of queries sent per site.
Answer: B
Explanation:
The most effective method for quality control (QC) of the query resolution process is to perform random audits of resolved query forms. This ensures that queries are being appropriately raised, addressed, and resolved in accordance with the study protocol, data management plan (DMP), and standard operating procedures (SOPs).
According to the GCDMP (Chapter: Data Validation and Cleaning), QC activities should verify that the data review and query management process maintains high accuracy and consistency. Random auditing of resolved queries enables verification that:
Queries were raised for legitimate discrepancies,
The site's responses were appropriate, and
The resolution actions taken by data management were correct and well-documented.
Metrics such as turnaround time (options A and C) or query counts (option B) measure efficiency but do not assess quality. True quality control focuses on ensuring that data corrections preserve accuracy, auditability, and traceability - the fundamental principles of data integrity in clinical research.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 5.4 - Query Management and Quality Control ICH E6 (R2) GCP, Section 5.5.3 - Data Integrity and Validation Procedures
NEW QUESTION # 44
Which of the following statements would be BEST included in a data management plan describing the process for making self-evident corrections in a clinical database?
- A. A senior level data manager may make audited changes to the database without further documentation.
- B. No changes will be made in the database without a query response signed by the investigator.
- C. Self-evident changes may be made per the listed conventions and documented to the investigative site.
- D. Self-evident corrections made in the database will be reviewed and approved by a team leader or manager.
Answer: C
Explanation:
A self-evident correction (SEC) refers to a data correction that is obvious, logical, and unambiguous - such as correcting an impossible date (e.g., 31-APR-2024) or standardizing a known abbreviation (e.g., "BP" to "Blood Pressure"). According to the Good Clinical Data Management Practices (GCDMP), SECs can be applied by data management staff following pre-approved conventions defined in the Data Management Plan (DMP).
The DMP should explicitly describe the criteria for SECs, including the types of errors eligible for this correction method, the required documentation, and the communication procedure to inform the investigative site. The process must maintain audit trail transparency and ensure that all changes are traceable and justified.
Options A and B suggest unauthorized or informal change procedures, which violate audit and compliance standards. Option C is too restrictive, as it prevents the efficient correction of non-clinical transcription or formatting errors.
Therefore, option D is correct: "Self-evident changes may be made per the listed conventions and documented to the investigative site." This approach aligns with CCDM expectations for balancing efficiency, accuracy, and regulatory compliance.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 6.2 - Self-Evident Corrections FDA 21 CFR Part 11 - Electronic Records; Audit Trails and Traceability Requirements
NEW QUESTION # 45
The result set from the query below would be which of the following?
SELECT * FROM patient WHERE medical_record_number > 9000
- A. Longer than the patient table
- B. Wider than the patient table
- C. Narrower than the patient table
- D. Shorter or of equal length than the patient table
Answer: D
Explanation:
In Structured Query Language (SQL), the WHERE clause is used to filter records based on specified criteria. The query retrieves all columns from the patient table (SELECT *) but only those rows where the medical_record_number value is greater than 9000.
This means:
The number of columns (fields) remains the same as the original table.
The number of rows (records) will be equal to or less than the number of rows in the patient table, depending on how many patients meet the filter condition.
Hence, the result set can only be shorter or equal in length compared to the original table. It cannot be longer, wider, or narrower, since no new rows or columns are created.
Therefore, option B - "Shorter or of equal length than the patient table" - is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 5.2 - Relational Database Queries and Filtering Logic ICH E6(R2) GCP, Section 5.5.3 - Data Retrieval, Filtering, and Storage Principles FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.4 - Query Logic and Record Subsetting
NEW QUESTION # 46
Which is the best way to see site variability in eligibility screening?
- A. List eligibility waivers by site
- B. Plot eligibility rate by site
- C. Summarize screening rate by site
- D. Graph enrollment by site
Answer: B
Explanation:
To identify site variability in eligibility screening, the most effective approach is to plot eligibility rate by site. This allows visual detection of differences in how well each site screens subjects according to protocol-defined inclusion and exclusion criteria.
The GCDMP (Chapter: Data Quality Assurance and Metrics) emphasizes the importance of graphical analysis for identifying anomalies and site-level performance variability. By plotting the eligibility rate by site, data managers and clinical operations teams can quickly identify outliers-sites that screen too many or too few eligible subjects-indicating potential training issues, misunderstanding of inclusion/exclusion criteria, or even possible protocol deviations.
While summarizing screening rate (B) provides useful numeric data, it lacks visual comparability. Listing waivers (A) or enrollment counts (C) provide limited insights into eligibility consistency.
Therefore, option D-Plot eligibility rate by site-is the best analytic and visualization practice to assess site variability in screening outcomes.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 6.1 - Use of Metrics and Graphical Review for Site Performance ICH E6(R2) GCP, Section 5.18.4 - Identification of Systematic or Site-Specific Issues
NEW QUESTION # 47
Which of the following data verification checks would most likely be included in a manual or visual data review step?
- A. Checking mandatory fields for missing values
- B. Checking a value against a reference range
- C. Checking an entered value against a valid list of values
- D. Checking adverse event treatments against concomitant medications
Answer: D
Explanation:
Manual or visual data review is used to identify complex clinical relationships and contextual inconsistencies that cannot be detected by automated edit checks.
According to the GCDMP (Chapter: Data Validation and Cleaning), automated edit checks are ideal for structured validations, such as missing fields (option C), reference ranges (option D), or predefined value lists (option A). However, certain clinical cross-checks-such as verifying adverse event treatments against concomitant medication records-require clinical judgment and contextual understanding.
For example, if an adverse event of "severe headache" was reported but no analgesic appears in the concomitant medication log, the data may warrant manual review and query generation. These context-based checks are best performed by trained data reviewers or medical data managers during manual data review cycles.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.3 - Manual Review and Clinical Data Consistency Checks ICH E6 (R2) Good Clinical Practice, Section 5.18.4 - Clinical Data Review Responsibilities FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Verification Principles
NEW QUESTION # 48
......
SCDM CCDM Exam Syllabus Topics:
| Topic | Details |
|---|---|
| Topic 1 |
|
| Topic 2 |
|
| Topic 3 |
|
| Topic 4 |
|
| Topic 5 |
|
Valid CCDM Exam Updates - 2026 Study Guide: https://lead2pass.prep4sureexam.com/CCDM-dumps-torrent.html